Analysis of the Efficacy of Salmeterol and Fluticasone on Different Serum Apolipoprotein A Levels in Patients With Chronic Obstructive Pulmonary Disease
Objective To analyze the therapeutic effects of salmeterol/fluticasone on patients with chronic obstructive pulmonary disease(COPD)with different serum apolipoprotein A levels,aiming to provide reference material for related research work.Methods A total of 176 COPD patients admitted to the People's Hospital of Liupanshui City from January 2021 to January 2023,were selected as the research subjects.Based on the difference in apolipoprotein A levels of the patients,they were divided into the high apolipoprotein group(n=100)and the low apolipoprotein group(n=76),with 0.6 g/L as the critical point.Patients were treated with salmeterol/fluticasone inhalation aerosol,with a dosage of 50 to 500 μg per time,once daily,for a period of 6 months.The lung function indicators,incidence of adverse reactions,and clinical symptom indicators between two groups of patients before and after intervention were compared.Results Before treatment,there was a statistically significant difference in the forced expiratory volume in one second(FEV1)and the forced expiratory volume in the first second in percent predicted values(FEV1%pred)between the two groups of patients(P<0.05).After treatment,the FEV1 and FEV1%pred of the two groups of patients improved compared to before intervention(P<0.05),and there was no statistically significant difference in the relevant data between groups after treatment(P>0.05).The incidence of adverse reactions in the low apolipoprotein group was 14.47%,and the incidence of adverse reactions in the high apolipoprotein group was 14.00%.There were no statistically significant difference in the incidence of adverse reactions between the two groups of patients(P>0.05).The hospitalization time,number of acute attacks,and interval between attacks in the low apolipoprotein group were were(15.98±0.18)days,(1.25±0.26)times,and(172.25±20.25)days,respectively;the high apolipoprotein group were(15.97±0.17)days,(1.24±0.25)times,and(171.98±20.26)days,respectively.There were no statistically significant difference in hospitalization time,number of acute attacks,and interval between attacks between the two groups of patients(P>0.05).Conclusion For COPD patients with different serum apolipoprotein A levels,the use of salmeterol and fluticasone to treat the disease can both achieve satisfactory results.The efficacy is not affected by the body's metabolic status,which is worth further promotion and application in clinical practice.
salmeterolserum apolipoprotein A levelchronic obstructive pulmonary diseasepulmonary functionadverse reactionefficacy analysis
NETL
NSTL
万方数据
